Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.

Comorbidities flag poor outcome on vedolizumab, ustekinumab for IBD

05 Oct 2020

In the treatment of patients with inflammatory bowel disease (IBD), comorbidities, but not patient age, influence the risk of any infection or hospitalizations on either vedolizumab or ustekinumab, a study suggests.

The analysis included 203 vedolizumab‐treated and 207 ustekinumab‐treated IBD patients. A total of 95 patients had one or more comorbidities (Charlson Comorbidity Index [CCI]; 49 and 46 in the respective groups). Sixty-three patients (15.4 percent) were aged 60 years, 140 (34.1 percent) between 40 and 60 years, and 206 (50.2 percent) <40 years. Of those in the oldest age group, 36 patients were treated with vedolizumab and 27 with ustekinumab.

Median treatment duration was 54.0 weeks with vedolizumab and 48.4 weeks with ustekinumab, with median follow‐up time of 104.0 and 52.0 weeks, respectively.

Multivariable logistic regression showed that CCI was significantly associated with the likelihood of any infection (odds ratio [OR], 1.387, 95 percent confidence interval [CI], 1.022–1.883; p=0.036) and hospitalization (OR, 1.586, 95 percent CI, 1.127–2.231; p=0.008) in the vedolizumab group, and also with hospitalization (OR, 1.621, 95 percent CI, 1.034–2.541; p=0.035) in the ustekinumab group.

CCI did not influence treatment efficacy. On the other hand, age was not associated with any outcomes.

The present data indicate that while the efficacy of both drugs is not impaired by the presence of comorbidities or a higher age, comorbidity status assessment should be performed to patients initiating vedolizumab or ustekinumab therapy in order to discuss additional safety risks, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.